ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Survey on the management of cancer associated thrombosis (CAT) in haemato-oncology patients with thrombocytopenia

1College of Medicine University of Nigeria Ituku Ozalla, Enugu, Enugu, Nigeria, 2University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers, Nigeria, 3Department of Haematology, Rivers State University Teaching Hospital Rivers state, Port Harcourt, Rivers, Nigeria, 4Department of Haematology and Blood Transfusion, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus Anambra state, Awka, Anambra, Nigeria, 5Pamo University of Medical Sciences, Iriebe Rivers State, Port Harcourt, Rivers, Nigeria, 6Department of Haematology and Immunology, Faculty of Basic Clinical Sciences, Abakaliki Ebonyi state, Abakaliki, Ebonyi, Nigeria

Abstract Number: PB0932

Meeting: ISTH 2022 Congress

Theme: Venous Thromboembolism » Cancer Associated Thrombosis

Background: Arterial or venous thrombosis can complicate cancer. Up to 20% of oncology patients develop venous thromboembolism (VTE), and VTE is not uncommon in haemato-oncology. However, haemoto-oncology is complicated by thrombocytopenia.

Aims: To access the knowledge and practice of haematologists in Nigeria as regards the management of thrombocytopenia and cancer-associated thrombosis (CAT).

Methods: This was a survey that was shared electronically with haematologists in Nigeria over a period of 6 months using a pretested questionnaire. The questionnaire tested participants’ knowledge and management practices of thrombocytopenia in CAT in haemato-oncology. Data were managed with Microsoft Excel and analysed using statistical package for social sciences version 21.

Results: We had 106 respondents, 70(66%) were Consultant Haematologists, about 30.2% of the respondents saw 6-10 haemato-oncology patients in a month. Fifty-Seven (53.8%) of the respondents risk assessed their patients for CAT, 63 (59.4%) of the respondents saw 1-2 haemato-oncology patients with thrombosis in 3 months. The most common mode of treatment was pharmacological – 94(88%) of respondents used low molecular weight heparin. The most common haemato-oncology associated with thrombocytopenia was Acute leukemias 69(67%). The most common decision taken by respondents was to stop anticoagulants and transfuse platelets because the most frequent concern was the risk of bleeding in this group of patients.

Conclusion(s): Many haematologists have a high level of awareness, knowledge, and good practice regarding thrombocytopenia in CAT in Haemato-oncology patients, however, there is a need for improved knowledge and unified protocols for treatment in line with newer treatment guidelines.

Imagine

Figure 1a: Number of haemato-oncology patients seen per month; Figure 1b: Frequency of thrombocytopenia in haemato-oncology patients.

To cite this abstract in AMA style:

Okoye H, Korubo K, Omunakwe H, Efobi C, Onodingene N, Ugwu N. Survey on the management of cancer associated thrombosis (CAT) in haemato-oncology patients with thrombocytopenia [abstract]. https://abstracts.isth.org/abstract/survey-on-the-management-of-cancer-associated-thrombosis-cat-in-haemato-oncology-patients-with-thrombocytopenia/. Accessed October 1, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/survey-on-the-management-of-cancer-associated-thrombosis-cat-in-haemato-oncology-patients-with-thrombocytopenia/